Executive leadership at Syra Health.
Board of directors at Syra Health.
Research analysts covering Syra Health.
Recent press releases and 8-K filings for SYRA.
Syra Health Appoints New CEO
SYRA
CEO Change
Management Change
Hiring
- Syra Health Corp. announced the appointment of Gregory R. Alexander as Chief Executive Officer, effective January 5, 2026.
- Alexander is a C-suite executive with over two decades of P&L experience, recognized for scaling healthcare organizations, driving growth, and exceeding financial targets.
- His experience includes expanding markets, tripling sales at CitizensRx, and growing Medicare Advantage membership by over 20% annually at Lumeris.
- The Board of Directors anticipates Alexander's deep expertise in Medicare, Medicaid, and population health will accelerate Syra Health's growth strategy and deliver value for shareholders.
Dec 18, 2025, 1:55 PM
Syra Health Corp. Announces Q3 2025 Financial Results
SYRA
Earnings
Demand Weakening
- Syra Health Corp. reported Q3 2025 revenue of $1.7 million, a decrease from $2.3 million in Q3 2024, primarily due to federal spending cuts, though its Population Health business unit grew 96% year-over-year.
- The company improved its gross margin to 33% in Q3 2025 from 30% in Q3 2024 and reduced its net loss by 46% year-over-year to ($225,902).
- Earnings per share improved to ($0.02) for Q3 2025 compared to ($0.06) for Q3 2024, and Adjusted EBITDA improved to ($218,601) from ($389,728) in the prior year period.
- Total operating expenses decreased 28% to $786,712 in Q3 2025, driven by a 43% reduction in salaries and benefits and a 12% decrease in selling, general, and administrative expenses.
Nov 12, 2025, 2:18 PM
Syra Health Announces Third Quarter 2025 Financial Results
SYRA
Earnings
Demand Weakening
- Syra Health reported Q3 2025 revenue of $1.7 million, a decline from $2.3 million in Q3 2024, primarily due to federal spending cuts.
- Despite the revenue decline, gross margin improved 300 basis points to 33% in Q3 2025 from 30% in Q3 2024, and net loss decreased 46% year-over-year to ($225,902), with EPS improving to ($0.02) from ($0.06) in Q3 2024.
- The Population Health business unit grew 96% year-over-year to $1,280,011 in Q3 2025, demonstrating strong market demand for its solutions.
- As of September 30, 2025, the company held $2.0 million in cash and had no long-term debt.
Nov 12, 2025, 12:55 PM
Quarterly earnings call transcripts for Syra Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more